Literature DB >> 28871415

Response to Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.

Evan Scullin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28871415     DOI： 10.1007/s40292-017-0230-3

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN： 1120-9879


× No keyword cloud information.
  3 in total

1.  Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Authors:  William C Cushman; George L Bakris; William B White; Michael A Weber; Domenic Sica; Andrew Roberts; Eric Lloyd; Stuart Kupfer
Journal:  Hypertension       Date:  2012-06-18       Impact factor: 10.190

2.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

3.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.